Dimerix Limited (ASX: DXB) has entered an exclusive license agreement with ADVANZ Pharma Corp. Limited (“ADVANZ”) for the commercialization of DMX-200, its Phase 3 drug candidate for focal segmental glomerulosclerosis (FSGS) kidney disease, in specific regions including the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand, following regulatory approval. Outside these regions, Dimerix retains commercialization rights. DMX-200 is currently in global Phase 3 clinical development, with the first analysis outcome expected by March 2024.
Dimerix will fund the global ACTION3 Phase 3 study for DMX-200 in FSGS patients, while ADVANZ will handle regulatory submissions and oversee sales and marketing within the licensed territories. Dimerix will receive an upfront payment of €6.5 million (~AU$10.8 million) within 30 days, along with potential development and commercialization milestones totalling up to €132 million (~AU$219 million).
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
